Nhi H. Vo, MD

Vascular & Interventional Radiologist. @BIDMCVIR @harvardmed trained. @RushMedical alumnus. Tweets=My Own

[Nhi H. Vo, MD @KnightsOfNhi]

Happy #Radtech week to the best #irad techs and nurses a girl can ask for.

[M. Saad Malik @Saad_MalikMD]

A novel precision-based tool in Y90, tumors w/ incomplete response had more ‘underdosed tumor’ (<100 Gy) on post PET/CT. Threshold analysis → ≥28% tumor got <100 Gy, odds of incomplete response ↑ (OR 75, univariate). Congrats @KnightsOfNhi, @AmmarSarwarIRad , & team @BIDMCVIR!

[Nhi H. Vo, MD @KnightsOfNhi]

@BIDMCVIR @BIDMChealth @harvardmed Congratulations Jess!! 👏

[Nhi H. Vo, MD @KnightsOfNhi]

@TaliFudimNP @BIDMCVIR @chirpa22 @SirNP_PASection Congratulations Tali! Excited to see what you do.

[Nhi H. Vo, MD @KnightsOfNhi]

@IR_Doctor Yes, definitely kept me busy! Ready for some 💤

[Nhi H. Vo, MD @KnightsOfNhi]

Been MIA, but your girl's been grinding. #Irad highlights from this week: mesenteric embo, CDT for CLTI, kypho/osteocool ablation x2, TIPS revision, LE venogram, hangman #filterout, and a Friday night special: PE thrombectomy 😵‍💫

[Julius Chapiro @JuliusChapiro]

We took a comprehensive look at the landscape of combination therapies of HCC, published today in @radiology_rsna @RSNA ! This state-of-the-art review should be a useful read for all disciplines involved in multi-disciplinary HCC care. Full article: https://t.co/67biFHNhGd

[Nhi H. Vo, MD @KnightsOfNhi]

@juliecbulman @benwhitemd @darnoldmedality Wow, congrats Julie! So well deserved!

[Ben White, MD @benwhitemd]

Congrats @juliecbulman and @darnoldmedality!

[BIDMC Vascular & Interventional Radiology @BIDMCVIR]

In this intensive @SIO_Central program, physicians can expect lectures, case reviews, and hands-on learning to help them implement or expand clinical techniques in their practices. And, our own Dr. Moussa is a co-course director!

Learn more/register: https://t.co/zh1CTXIU46

[Nhi H. Vo, MD @KnightsOfNhi]

@juliecbulman And you look great doing it. Happy birthday!!

[Julie Bulman, MD @juliecbulman]

Good luck to our 6 grads!!! June always hits hard with graduation - this year is no different, what an *amazing* class. You certainly made my job easy for me and brought countless laughs and memories. @BIDMCVIR will always be your home but go get ‘em 👊

[Nhi H. Vo, MD @KnightsOfNhi]

@BIDMCVIR @juliecbulman @MuneebAhmedIR @BIDMCRad

[Nhi H. Vo, MD @KnightsOfNhi]

That's a good looking Section of the Year 🏆. Thank you #irad fam for an incredible journey.

[Nhi H. Vo, MD @KnightsOfNhi]

@sethb_md @SIRspecialists @ajgunnmd @MoonJustaniah @keithppereira @RamChadalavada @TheRealDoctorOs @rahulshethmd Congrats Seth! Well deserved

[BIDMC Vascular & Interventional Radiology @BIDMCVIR]

📰#SIR24SLC News:

🎉Congratulations to Dr. Weinstein for receiving one of the @JVIRmedia Paper of the Year awards for his hand-motion work!

🎉Congrats also to @AmmarSarwarIRad, who received an award for having one of the most downloaded papers in 2023: https://t.co/qMPX6qhkKe

[Nhi H. Vo, MD @KnightsOfNhi]

@juliecbulman @sethb_md @SIRspecialists @BIDMCVIR Yes, yes they are @sethb_md

[Nhi H. Vo, MD @KnightsOfNhi]

@BobLeeMD Had a bowl cut in kindergarten and apgars were 5... Think they'll let me in? 😬

[Nhi H. Vo, MD @KnightsOfNhi]

@DHidlayVIR Good to know! Here I am hoping Facebook memories will pull through! ;P

[iRadPulse @iRadPulse]

📢 NEW from @JVIRmedia: Comparing Microwave Ablation (MWA) vs Cryoablation (CA) for small renal masses!

A 12-year single-center study offers valuable insights. Let's break it down! 📊🔬 @SIRspecialists

Study Details:

• 279 small renal masses (≤ 4cm) in 257 patients
• Median age: 71 years
• CA: 191 cases; MWA: 88 cases
• Evaluated: Adverse events, treatment effectiveness, survival rates 🔎

Key Results:

• MWA: 100% technical success
• CA: 1/191 needed retreatment
• No significant impact on renal function post-treatment (CA: p=0.76, MWA: p=0.49)
• No major differences in local recurrence, adverse events, or survival rates 📈🩺

In-Depth Analysis:

• CA used for larger (p<0.01), more complex lesions (p=0.03)
• Propensity score matching showed:
🔹 Similar local recurrence rates (p=0.39)
🔹 Comparable adverse event rates (p=0.20)
🔹 Equivalent cancer-free & overall survival (p=0.76, p=0.19) 🔍

�� Conclusion: Both MWA & CA show high technical success and effective local disease control. Cancer-specific survival rates are similar. CA's higher adverse event rates may be due to treating larger lesions.

Read the full study: https://t.co/QiOyUQI0nM

A big thank you to the authors for their contribution @AmandaSmolockMD, @kantonIR, @DrRobertAdamo, & team! 🙏

How might these findings influence your approach to treating small renal masses? Stay informed on the latest research with our newsletter: https://t.co/s4KXlO0vPJ

@UWiscRadiology @JEFFUrology @JeffCVIR
#VIR #iRads #InnovationInMedicine #MedEd #EvidenceBasedMedicine #Healthcare #ClinicalOutcomes #PatientSafety #MedicalResearch #CancerTreatment #Urology #RenalCellCarcinoma #Oncology #Radiology #InterventionalRadiology